Argenica Therapeutics is a clinical stage drug development company focused on developing novel neuroprotective therapeutics for stroke and other types of acute brain injuries. Their lead candidate, ARG-007, is designed to protect brain cells and reduce cell death following stroke and other neurological trauma, with the aim of improving patient recovery outcomes. Based in Western Australia, Argenica is progressing through clinical trials towards commercialisation of its neuroprotective drug.
Is this your organisation?
Claim this profile to add your story, team and milestones.